24H | Chimerix Shares Soar 173% as Company Plans FDA Submission of Cancer Drug Dordaviprone

Dow Jones12-10

Shares of Chimerix have topped 52-week highs following news the biopharmaceutical company plans to submit Dordaviprone for accelerated approval to the Food and Drug Administration before the end of the year.

The company's shares, which closed Monday's regular session at 86.5 cents, surged 172.36% to $2.36 in overnight trading.

The stock hit a 52-week high of $1.30 on March 8.

Chimerix said it was seeking accelerated approval for Dordaviprone as a treatment for certain patients with diffuse glioma, a type of brain cancer.

The company said Dordaviprone has received rare pediatric disease designation for H3 K27M-mutant glioma, adding it intends to apply for a rare pediatric disease priority review voucher in the upcoming NDA submission.

Mike Andriole, chief executive, said Chimerix bolstered it commercial leadership team and will be ready for a U.S. launch as early as the third quarter of next year, pending application acceptance and priority review, if granted.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490089468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490089468","market":"hk","top_or_hot":-1,"title":"24H | Chimerix Shares Soar 173% as Company Plans FDA Submission of Cancer Drug Dordaviprone","media":"Dow Jones","content":"<html><head></head><body><p>Shares of Chimerix have topped 52-week highs following news the biopharmaceutical company plans to submit Dordaviprone for accelerated approval to the Food and Drug Administration before the end of the year.</p><p>The company&#39;s shares, which closed Monday&#39;s regular session at 86.5 cents, surged 172.36% to $2.36 in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d1fe9b5cf96e0e3afc4bdf0f2515b4f5\" tg-width=\"799\" tg-height=\"607\"/></p><p>The stock hit a 52-week high of $1.30 on March 8.</p><p>Chimerix said it was seeking accelerated approval for Dordaviprone as a treatment for certain patients with diffuse glioma, a type of brain cancer.</p><p>The company said Dordaviprone has received rare pediatric disease designation for H3 K27M-mutant glioma, adding it intends to apply for a rare pediatric disease priority review voucher in the upcoming NDA submission.</p><p>Mike Andriole, chief executive, said Chimerix bolstered it commercial leadership team and will be ready for a U.S. launch as early as the third quarter of next year, pending application acceptance and priority review, if granted.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>24H | Chimerix Shares Soar 173% as Company Plans FDA Submission of Cancer Drug Dordaviprone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n24H | Chimerix Shares Soar 173% as Company Plans FDA Submission of Cancer Drug Dordaviprone\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 10:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Chimerix have topped 52-week highs following news the biopharmaceutical company plans to submit Dordaviprone for accelerated approval to the Food and Drug Administration before the end of ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMRX","symbol_name":"Chimerix Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490089468","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490089468","pubTimestamp":1733796272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Chimerix have topped 52-week highs following news the biopharmaceutical company plans to submit Dordaviprone for accelerated approval to the Food and Drug Administration before the end of the year.The company's shares, which closed Monday's regular session at 86.5 cents, surged 172.36% to $2.36 in overnight trading.The stock hit a 52-week high of $1.30 on March 8.Chimerix said it was seeking accelerated approval for Dordaviprone as a treatment for certain patients with diffuse glioma, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMRX":"Chimerix Inc.","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"24小时Chimerix股价飙升173%，公司计划向FDA提交抗癌药物Dordaviprone","themeId":"8c205cbbfdc97b958f2129041ebc6a1f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMRX":1},"content_text":"Shares of Chimerix have topped 52-week highs following news the biopharmaceutical company plans to submit Dordaviprone for accelerated approval to the Food and Drug Administration before the end of the year.The company's shares, which closed Monday's regular session at 86.5 cents, surged 172.36% to $2.36 in overnight trading.The stock hit a 52-week high of $1.30 on March 8.Chimerix said it was seeking accelerated approval for Dordaviprone as a treatment for certain patients with diffuse glioma, a type of brain cancer.The company said Dordaviprone has received rare pediatric disease designation for H3 K27M-mutant glioma, adding it intends to apply for a rare pediatric disease priority review voucher in the upcoming NDA submission.Mike Andriole, chief executive, said Chimerix bolstered it commercial leadership team and will be ready for a U.S. launch as early as the third quarter of next year, pending application acceptance and priority review, if granted.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490089468"}